Apitegromab

Rather than blocking mature myostatin or its receptor, apitegromab binds the inactive precursor forms - promyostatin and latent myostatin - and stops them being cleaved into the active ligand. This is a deliberately upstream and highly selective approach: it leaves activins, GDF-11 and BMP signalling untouched, which is exactly the design goal after ACE-031's broad ligand trapping produced bleeding and telangiectasia. The consequence is a much cleaner safety profile, with no vascular signal reported. The trade-off is that pure myostatin blockade produces more modest effects than broad ActRII blockade, and in muscle that has already lost motor neuron input, blocking myostatin only helps to the extent that innervation has been restored by an SMN-directed therapy.

Targets: Promyostatin, Latent myostatin, Myostatin activation (proteolytic)

• · 10 or 20 mg/kg every four weeks. Microgram figures are per kilogram of body weight.
• · 20 mg/kg monthly. Preserved a statistically significant share of lean mass versus tirzepatide alone.

Work out your exact syringe units →

• commonHeadache
• commonPyrexia and upper respiratory infection— Common in the paediatric SMA trial population.
• uncommonInfusion-related reaction
• uncommonAnti-drug antibodies— Reported without clear clinical consequence so far.
• rareNotably absent: bleeding and telangiectasia— The selective design appears to have successfully avoided the ACE-031 vascular signal.

• Pregnancy and breastfeeding.
• Known hypersensitivity to the antibody.
• Outside a trial or approved indication there is simply no legitimate access route.

• synergytirzepatide — The EMBRAZE phase 2 trial showed significantly preserved lean mass during tirzepatide-induced weight loss.
• redundantbimagrumab — Overlapping mechanism, different selectivity.
• redundantace-031 — Same pathway; apitegromab was designed to be the safer version.

• · DEXA body composition in the obesity setting.
• · Motor function scales (HFMSE, RULM) in the SMA setting.
• · Standard biologic safety labs.

Not yet approved anywhere as of mid-2026; BLA under FDA review with a September 2026 action date and an EMA application pending. Prohibited in sport by WADA.

• SAPPHIRE phase 3 trial of apitegromab in non-ambulatory spinal muscular atrophy (trial)
• EMBRAZE phase 2 trial of apitegromab with tirzepatide showing lean mass preservation (2025) (trial)
• Scholar Rock BLA resubmission and FDA acceptance with 30 September 2026 PDUFA date (other)

Apitegromab is the field's answer to everything that went wrong with broad ActRII blockade, and its mechanism is a genuinely elegant piece of drug design. Myostatin is made as a precursor: the propeptide and the growth-factor domain are cleaved but stay associated as a latent complex, and the growth factor is only liberated when a tolloid protease cuts the propeptide. Apitegromab binds the pro- and latent forms and prevents that final activation step. Because it never touches the mature dimer and never touches the receptor, it cannot interfere with activin A, activin B, GDF11 or any BMP - which means no FSH suppression, no BMP9/BMP10-related vascular problem, none of the reasons ACE-031 was stopped. The trade is selectivity for magnitude: you are blocking exactly one ligand out of the several that restrain muscle, and Lach-Trifilieff's mouse work already showed that blocking myostatin alone leaves growth on the table relative to receptor blockade. That trade shows up in the clinical data. SAPPHIRE, a properly powered 188-patient phase 3 in nonambulatory type 2 and type 3 spinal muscular atrophy on background nusinersen or risdiplam, met its primary endpoint with a least-squares mean difference in Hammersmith Expanded score change of 1.8 points (95% CI 0.30 to 3.32, p=0.019) for the combined doses at 12 months. Real, statistically significant, and modest - and the 20 mg/kg dose alone did not reach significance at p=0.11, which is the kind of detail that gets dropped from summaries. Safety was the headline: adverse event incidence and severity similar to placebo, most commonly pyrexia, nasopharyngitis and cough, and no discontinuations for adverse events. Then EMBRAZE tested the body-composition question directly - 102 overweight or obese adults, apitegromab plus an incretin mimetic versus placebo plus incretin mimetic, with change in total lean body mass on DXA at 24 weeks as the primary endpoint. That is the trial design that matters for anyone reading this for physique reasons, and it is completed.

The realistic disappointment with apitegromab is magnitude. A 1.8-point HFMSE difference is a genuine phase 3 win and it is small, and the higher dose arm did not separate from placebo on its own. Selectivity was bought at a price. Anyone expecting Belgian Blue physiology from an antibody that blocks the activation of one ligand out of several should read the SAPPHIRE numbers carefully. The second issue is that the population studied is nothing like the reader: children and young adults with SMA who are nonambulatory and on background disease-modifying therapy. Extrapolating an HFMSE change in that group to hypertrophy in a trained adult is not a small leap. The third is supply: this is a humanised monoclonal antibody dosed at 10-20 mg/kg intravenously, which means 700-1400 mg per infusion for an adult. That is grams per year of a mammalian-cell-produced biologic, and there is no grey-market pathway that produces it. Anything sold as apitegromab outside a trial is almost certainly not.

• Pro-myostatin and latent myostatin — High-affinity selective binding to the precursor forms; exact Kd not published in the sources resolved here

  Prevents tolloid-mediated proteolytic activation, so mature myostatin is never liberated. Serum latent myostatin rises on treatment, which is how target engagement is confirmed.

• Mature myostatin dimer — Not bound

  None. This is deliberate - the antibody works upstream of activation rather than intercepting the active ligand.

• GDF11, activin A, activin B, BMPs — No meaningful binding

  None, and this is the point. The absence of activin and BMP interference is why apitegromab has a placebo-like safety profile where ACE-031 had telangiectasia and epistaxis.

• SAPPHIRE - Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (NCT05156320) Phase 3 · n=188 · 52 weeks · 2025

  Change in Hammersmith Functional Motor Scale Expanded at 12 months in patients already on nusinersen or risdiplam. Combined apitegromab doses gave a least-squares mean difference of 1.8 points (95% CI 0.30 to 3.32, p=0.019) versus placebo. The 20 mg/kg dose alone did not reach significance (p=0.11). 156 patients aged 2-12 randomised 1:1:1 to 20 mg/kg, 10 mg/kg or placebo every 4 weeks; 32 aged 13-21 randomised 2:1 to 20 mg/kg or placebo. Adverse event incidence and severity similar to placebo; no discontinuations for adverse events.

• TOPAZ - Phase 2 study of apitegromab in spinal muscular atrophy types 2 and 3 (NCT03921528) Phase 2 · n=58 · 2024

  Safety and efficacy of apitegromab in SMA types 2 and 3, with motor function scales as the efficacy readout. A 36-month extension analysis reported long-term efficacy, safety and patient-reported outcomes.

• EMBRAZE - Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese (NCT06445075) Phase 2 · n=102 · 24 weeks

  Change from baseline in total lean body mass by DXA at 24 weeks, in adults receiving apitegromab plus an incretin mimetic versus placebo plus an incretin mimetic. Randomised, double-blind, placebo-controlled, quadruple-masked. Listed as completed on ClinicalTrials.gov.

• ONYX - Long-term safety and efficacy of apitegromab in patients with SMA who completed previous apitegromab trials (NCT05626855) Phase 3 · n=238

  Long-term safety and efficacy extension. Listed as active, not recruiting on ClinicalTrials.gov.

Serum latent myostatin rises within weeks of the first dose, and that is the only fast readout. Functional and motor scale changes in SMA were assessed at 12 months. In the obesity setting the primary endpoint was lean mass at 24 weeks. Nothing about this drug produces a noticeable effect in days.

The evidence-backed combination is with an incretin mimetic, which is exactly what EMBRAZE tested: apitegromab plus a GLP-1 agonist in overweight and obese adults with DXA lean mass as the primary endpoint. That is the modern design for this whole class - let the incretin create the deficit, let the myostatin blocker protect what the deficit takes. In SMA it is layered on top of nusinersen or risdiplam, which is a different logic: the disease-modifying drug preserves motor neurons and the myostatin blocker addresses the muscle. Do not combine apitegromab with bimagrumab, ACE-031, follistatin or trevogrumab - they converge on one pathway and stacking them buys the broad-blockade risk profile that apitegromab exists to avoid. Combination with androgens or GH is mechanistically independent and untested.

Against bimagrumab: apitegromab is the selective end of the same axis. Bimagrumab blocks both activin receptors and gets a substantially larger body-composition effect - 7.5 kg of fat and 1.7 kg of lean mass in the diabetes trial - at the cost of muscle spasms, diarrhoea and acne. Apitegromab gets a smaller effect with a safety profile that was statistically indistinguishable from placebo in a 188-patient phase 3. That is the trade in this class, stated as plainly as the data allow. Against ACE-031: apitegromab is what the field built after ACE-031's telangiectasia signal, and its selectivity for pro-myostatin is a direct engineering response to that failure. Against trevogrumab: both are anti-myostatin antibodies, but trevogrumab targets mature myostatin while apitegromab targets the precursor, and trevogrumab is being developed in combination with garetosmab, an anti-activin A antibody - which is Regeneron rebuilding the broad blockade deliberately and one ligand at a time. Against follistatin and the grey-market compounds, there is no comparison to draw: apitegromab has a phase 3 result and they have none.

Not approved at the time of writing and therefore without a market price. Weight-based intravenous dosing at 10-20 mg/kg every four weeks means gram-scale annual consumption of a monoclonal antibody, which places it firmly in specialty-biologic territory.

• ?Numeric pharmacokinetic parameters - half-life, clearance, volume of distribution, time to steady state - were not resolved to a primary source in this session.
• ?The binding affinity of apitegromab for pro- and latent myostatin was not published in the sources reviewed.
• ?EMBRAZE is completed but its results were not resolved here, so the effect on lean mass during incretin-driven weight loss is not yet stated as a number.
• ?Whether myostatin blockade in a healthy trained adult produces anything like the effect seen in a disease population is untested and should not be assumed.
• ?The antibody isotype is described in the literature as a humanised monoclonal; the exact isotype and sequence were not confirmed here.
• ?Long-term effects beyond the 36-month TOPAZ extension are unknown.

• Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial Crawford TO, Servais L, Mercuri E, et al.; SAPPHIRE Study Group, Lancet Neurology, 2025 · PMID 40818473

  The only phase 3 result for any myostatin-targeting drug. Source of the 1.8-point HFMSE difference, the p values including the non-significant 20 mg/kg arm, and the placebo-like safety profile.

• Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study Crawford TO, et al., Neurology, 2024 · PMID 38330285

  The phase 2 that justified SAPPHIRE.

• Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study Crawford TO, et al., Frontiers in Neurology, 2024 · PMID 39105058

  Three years of continuous dosing data - the longest safety exposure available for selective myostatin blockade in humans.

• A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation Cote SM, et al., SLAS Discovery, 2020 · PMID 31347449

  Confirms both the mechanism - inhibition of myostatin activation rather than of the mature ligand - and the existence of a validated serum latent myostatin target-engagement assay.